Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IART Stock Forecast 2026-2027
$16.94
Current Price
$1.32B
Market Cap
Buy 2
Hold 6
Sell 2
Wall St Analyst Ratings
Distance to IART Price Targets
+59.4%
To High Target of $27.00
-11.5%
To Median Target of $15.00
-35.1%
To Low Target of $11.00
IART Price Momentum
+8.1%
1 Week Change
+21.7%
1 Month Change
+22.0%
1 Year Change
+36.4%
Year-to-Date Change
-5.0%
From 52W High of $17.83
+94.7%
From 52W Low of $8.70
📊 TOP ANALYST CALLS
Did IART Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Integra is one of their latest high-conviction picks.
Latest IART Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, IART has a neutral consensus with a median price target of $15.00 (ranging from $11.00 to $27.00). The overall analyst rating is Buy (6.2/10). Currently trading at $16.94, the median forecast implies a -11.5% downside. This outlook is supported by 2 Buy, 6 Hold, and 2 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IART Analyst Ratings
2
Buy
6
Hold
2
Sell
IART Price Target Range
Low
$11.00
Average
$15.00
High
$27.00
Current: $16.94
Latest IART Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IART.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 28, 2026 | Citigroup | Joanne Wuensch | Neutral | Upgrade | $16.00 |
| May 6, 2026 | Citigroup | Sell | Maintains | $N/A | |
| May 6, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Apr 15, 2026 | Truist Securities | Hold | Maintains | $N/A | |
| Apr 15, 2026 | Argus Research | Hold | Downgrade | $N/A | |
| Mar 11, 2026 | Citigroup | Sell | Maintains | $N/A | |
| Feb 27, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Nov 3, 2025 | Truist Securities | Hold | Reiterates | $N/A | |
| Oct 31, 2025 | Citigroup | Sell | Maintains | $N/A | |
| Oct 31, 2025 | JP Morgan | Underweight | Maintains | $N/A | |
| Oct 15, 2025 | Truist Securities | Hold | Maintains | $N/A | |
| Oct 7, 2025 | Citigroup | Sell | Maintains | $N/A | |
| May 9, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| May 6, 2025 | JP Morgan | Underweight | Maintains | $N/A | |
| May 6, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Apr 11, 2025 | Truist Securities | Hold | Maintains | $N/A | |
| Mar 31, 2025 | Argus Research | Buy | Upgrade | $N/A | |
| Feb 26, 2025 | Citizens Capital Markets | Market Outperform | Reiterates | $N/A | |
| Nov 5, 2024 | Citigroup | Sell | Maintains | $N/A | |
| Oct 14, 2024 | Truist Securities | Hold | Maintains | $N/A |
Integra LifeSciences Holdings Corporation (IART) Competitors
The following stocks are similar to Integra based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Integra LifeSciences Holdings Corporation (IART) Financial Data
Integra LifeSciences Holdings Corporation has a market capitalization of $1.32B with a P/E ratio of 66.5x. The company generates $1.64B in trailing twelve-month revenue with a -30.1% profit margin.
Revenue growth is +2.4% quarter-over-quarter, while maintaining an operating margin of +10.4% and return on equity of -38.6%.
Valuation Metrics
Market Cap
$1.32B
Enterprise Value
$3.10B
P/E Ratio
66.5x
PEG Ratio
-0.8x
Price/Sales
0.8x
Growth & Margins
Revenue Growth (YoY)
+2.4%
Gross Margin
+55.4%
Operating Margin
+10.4%
Net Margin
-30.1%
EPS Growth
+2.4%
Financial Health
Cash/Price Ratio
+20.1%
Current Ratio
3.4x
Debt/Equity
195.8x
ROE
-38.6%
ROA
+2.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Integra LifeSciences Holdings Corporation (IART) Business Model
About Integra LifeSciences Holdings Corporation
What They Do
Global medical technology company for surgical solutions.
Business Model
The company generates revenue through two main segments: Codman Specialty Surgical, which produces specialized neurosurgical instruments and devices, and Tissue Technologies, focused on regenerative medicine products. By offering a diverse range of innovative medical products, Integra serves healthcare professionals and institutions worldwide, leveraging both direct sales and distribution channels.
Additional Information
Integra LifeSciences operates in over 120 countries and emphasizes clinical evidence in its product development, providing a strong foundation for its offerings in precision surgical instruments and implants. Founded in 1989 and based in Princeton, New Jersey, the company has a significant presence in North America and is expanding its international reach.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
4,396
CEO
Ms. Mojdeh Poul
Country
United States
IPO Year
1995
Website
www.integralife.comIntegra LifeSciences Holdings Corporation (IART) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Here's Why You Should Retain NVST Stock in Your Portfolio for Now
Envista is expanding globally, launching new products and boosting margins, but can growth initiatives outweigh tariff, FX and China-related risks?
Jun 08, 2026
By Zacks Equity Research
Analyst Blog
Why Is Integra (IART) Up 15% Since Last Earnings Report?
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 04, 2026
By Zacks Equity Research
Realtime BLOG
Is Omnicell Stock a Smart Addition to Your Portfolio Now?
OMCL rides on SaaS growth, Autonomous Pharmacy adoption and expansion plans, but rising costs and competition could test its momentum.
Jun 04, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Integra (IART) recently reported earnings, and investors are now looking ahead to future developments impacting the stock.
Why It Matters
Integra's recent earnings report may influence investor sentiment, affecting stock performance and future price movements based on financial health and growth outlook.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Integra LifeSciences (Nasdaq: IART) CFO Lea Knight will present at the Jefferies Global Healthcare Conference on June 3, 2026, at 10:30 AM ET.
Why It Matters
CFO presentations can signal company strategy and financial health. This event may influence investor sentiment and stock performance based on insights shared during the conference.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Integra LifeSciences (IART) and Masimo (MASI) are notable stocks in the Medical - Instruments sector, with current discussions on which offers better value for investors.
Why It Matters
The comparison of Integra LifeSciences and Masimo highlights potential investment opportunities, prompting investors to evaluate which stock offers better value for their portfolios.
Source: Zacks Investment Research
Market Sentiment:
Positive
Integra LifeSciences Holdings Corporation (IART) Hit a 52 Week High, Can the Run Continue?
11 days ago
Quick Summary
Integra (IART) has reached a 52-week high. Investors may want to evaluate the company's fundamentals for potential future gains.
Why It Matters
Integra's 52-week high indicates strong market performance, suggesting potential momentum. Analyzing fundamentals can reveal sustainability of growth, influencing future investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Zacks Style Scores can assist investors in selecting strong, market-beating stocks for their portfolios.
Why It Matters
Zacks Style Scores can guide investors in identifying high-potential stocks, enhancing portfolio performance and potentially leading to better returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Four GARP stocks with discounted PEG ratios and strong growth potential are highlighted as offering a balanced investment strategy for 2026.
Why It Matters
GARP stocks with discounted PEG ratios and strong growth potential indicate value and growth opportunities, appealing to investors seeking balanced returns in 2026.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About IART Stock
What is Integra LifeSciences Holdings Corporation's (IART) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Integra LifeSciences Holdings Corporation (IART) has a median price target of $15.00. The highest price target is $27.00 and the lowest is $11.00.
Is IART stock a good investment in 2026?
According to current analyst ratings, IART has 2 Buy ratings, 6 Hold ratings, and 2 Sell ratings. The stock is currently trading at $16.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IART stock?
Wall Street analysts predict IART stock could reach $15.00 in the next 12 months. This represents a -11.5% decrease from the current price of $16.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Integra LifeSciences Holdings Corporation's business model?
The company generates revenue through two main segments: Codman Specialty Surgical, which produces specialized neurosurgical instruments and devices, and Tissue Technologies, focused on regenerative medicine products. By offering a diverse range of innovative medical products, Integra serves healthcare professionals and institutions worldwide, leveraging both direct sales and distribution channels.
What is the highest forecasted price for IART Integra LifeSciences Holdings Corporation?
The highest price target for IART is $27.00 from at , which represents a 59.4% increase from the current price of $16.94.
What is the lowest forecasted price for IART Integra LifeSciences Holdings Corporation?
The lowest price target for IART is $11.00 from at , which represents a -35.1% decrease from the current price of $16.94.
What is the overall IART consensus from analysts for Integra LifeSciences Holdings Corporation?
The overall analyst consensus for IART is neutral. Out of 2 Wall Street analysts, 2 rate it as Buy, 6 as Hold, and 2 as Sell, with a median price target of $15.00.
How accurate are IART stock price projections?
Stock price projections, including those for Integra LifeSciences Holdings Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 2:58 AM UTC